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As the financial drivers in U.S. health care 
shift from volume-linked reimbursement 
toward payment based on episodes of care, 
medical outcomes and quality, Jefferson 
graduates have a distinct advantage. 
Medicine is indeed both an art and a 
science. On the science side of the ledger, 
our knowledge of disease pathophysiology, 
our diagnostic arsenal and our therapeutic 
options have all increased dramatically 
over the past 50 years. Yet there remains 
a critical component of medicine that is 
still an art, one that forms in many ways 
the basis for the intangible doctor-patient 
relationship at the very core of the medical 
profession. Certainly, a clinical history can 
be obtained using a computer to interro-
gate a patient before the physician arrives. 
This method is more efficient, perhaps, but 
lacks the personal contact of a concerned 
physician speaking directly to an anxious 
patient. Likewise, a battery of initial labora-
tory tests might provide quantifiable clues 
about that patient’s illness, but the laying 
on of the physician’s hands in a skillful 
physical examination will often yield those 
insights more quickly, while at the same 
time strengthening the supportive and ther-
apeutic bond that must develop between 
patient and physician. It would indeed be 
a tragedy if modern medicine lost the value 
of the “art” because of the overwhelming 
pursuit of the “science.”
As a generation of senior faculty begins 
to retire, instruction in these clinical diag-
nostic skills is becoming a lost art at many 
other medical schools. Physicians trained at 
Jefferson have the best of both worlds. They 
are fully versed in the science of medicine 
and skillfully deploy the latest medical tech-
nologies, techniques and diagnostic studies. 
But they’re also equipped with a deep appre-
ciation for the art of medicine, including the 
elucidation of the medical history and the 
physical exam that still form a critical basis 
of our profession.
In my own specialty of neurology, the art 
of clinical observation was a highly refined 
skill in the generation of clinicians who were 
my mentors and role models. Even now, I 
learn more about a new patient’s problems 
merely by observing him walking into my 
office than I do from all the forms he filled 
out prior to being called into consultation. 
Before my patient even says hello, I know a 
tremendous amount: how he gets up from a 
chair, what his gait looks like, how he carries 
his arms or how his eyes move. This focuses 
the history I take and helps me identify 
whether the primary complaint is the core 
problem or a symptom of a condition the 
patient doesn’t know about yet. While a full 
neurological exam could take hours, like 
other neurologists with my training, I have 
already picked through the tree of physical 
diagnoses as applied to what I have seen 
and heard and can efficiently streamline 
my interactions without sacrificing clin-
ical accuracy. Physicians with such skills 
can develop a differential diagnosis in their 
minds that others might only obtain by 
ordering layers of tests. 
Jefferson has imbued its graduates with 
expertise in physical diagnosis for nearly 200 
years. Today, our curriculum explicitly rein-
forces these skills. We provide structured 
practice with standardized and simulated 
patients at Jefferson’s Clinical Skills and 
Simulation Center. Our faculty teach new 
ways to use old-fashioned tools, such as 
a stethoscope, to assess the heart, liver, 
lungs and even bowels. They demonstrate 
and validate students’ auditory detection 
skills, for instance, by using a stethoscope 
connected to infrared headphones that allow 
students and faculty to listen to the same 
sounds simultaneously.
As a result, our graduates know how to 
take a clear and accurate patient history, how 
to use their senses and intuition in a physical 
exam to accelerate the path toward diagnosis 
and, not least, how to express concern and 
caring. They have a more balanced view of 
the patient and his or her disease rather than 
treating a patient as a set of symptoms and 
laboratory studies. 
Physical diagnosis skills are part of what 
elevate a technically skilled physician to a 
truly great clinician who doesn’t waste time 
or money getting to a correct diagnosis. 
Technology and testing are essential tools 
to confirm or narrow down a differential 
diagnosis and identify an effective course 
of treatment. But they should never be a 
crutch. Physicians who lack physical diag-
nosis skills tend to order significantly more 
studies and scans. 
As the economics of health care continue to 
evolve, Jefferson-trained physicians possess a 
competitive advantage that will serve them 
well. We pass along this legacy of physical 
diagnosis skills, derived from the collective 
wisdom of earlier generations of physicians, 
not as a romantic notion or historical artifact 
but as a necessity for accurate and efficient 
diagnosis and treatment. 
At Jefferson, we teach physical diagnosis 
skills because it’s good medicine. 
Sincerely,
 
 
Robert L. Barchi, MD, PhD 
President 
Thomas Jefferson University
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In our metric-centric administrative culture, 
medical schools are too commonly compared 
on the basis of that which is most readily 
quantifiable – college grade point averages 
and MCAT scores of incoming students loom 
large. Simplistic metrics such as these, rein-
forced by magazines catering to the allure of 
“the best of this” and “the best of that” rank-
ings, do a disservice to our training programs, 
along with our profession at large. Through 
their distorting lens, these evaluation schema 
fail to register the most meaningful personal 
attributes, the most impressive life accom-
plishments and the real potential of our 
students. No one has designed a compelling 
metric that fully captures the deeper human 
qualities that truly distinguish one’s students 
– the characteristics that drive a medical 
school’s vibrancy and culture, and those 
that predict how trainees will instantiate the 
highest aspirations of their medical training 
within society. 
The heart and soul of Jefferson are so 
much more than the grades and scores of 
its students – they are reflected in their life 
experiences. We recruit students who have 
the broad range of intellectual and personal 
skills needed for successful and varied careers 
in medicine. Yes, these are students who 
routinely emerge from their training as expert 
diagnosticians and empathic caregivers. But 
more than this, we are looking to them to 
become leaders – in dimensions ranging from 
discovery science to medical education to 
healthcare reform. Our goal is to generate a 
cadre of physicians who can function well in 
diverse healthcare and societal settings. This 
starts with the admission process. Diversity of 
input allows for diversity of output.
This issue contains a fascinating profile of 
Kanani Titchen, a former professional actor 
who today is a fourth-year student (see page 
18). As an aspiring pediatrician, Kanani’s capa-
bilities were enriched by her years acting with a 
theatrical repertory company, which strength-
ened her communication skills and deepened 
her understanding of the human spirit. 
As we celebrated the 50th anniversary of 
women at JMC this past year, we were treated 
to many vivid examples of the nontraditional 
paths JMC women have taken to medicine, 
past and present. I’d like to share just a few 
from our current crew. Of course, the men of 
our student body have similarly fascinating 
backgrounds, but I’ll save their stories for 
some other time.
As one of the founders of Philadelphia’s all-
women roller derby league, Kristi Dellabadia 
traveled a circuitous route to medicine that 
in retrospect makes perfect sense. After 
high school, she obtained a two-year certifi-
cate as a veterinary technician. Kristi then 
spent a decade working in critical care at 
the University of Pennsylvania’s Matthew J. 
Ryan Veterinary Hospital. A benefit of that 
daytime job, free tuition, allowed her to earn 
a bachelor degree in biology at night.
During those busy years, Kristi helped 
launch Philly Roller Girls, which promotes 
itself as a “league of athletic, ferocious, kick-
ass chicks on wheels,” and competed with 
the Liberty Belles travel team. Initially, she 
considered becoming a veterinarian, but soon 
realized that she felt more fulfilled meeting 
the medical needs of people. As a 33-year-old 
second-year medical student, she feels that all 
those experiences help her listen to patients 
more effectively and ask the right questions.
Joanelle Bailey discovered an interest in 
medicine when she explored alternatives to 
her first job out of college as a civil engineer. 
During her two years at that job, Bailey 
became a volunteer fire fighter. Training 
included an EMT class with a mandatory 
ambulance ride-along. Bailey soon realized 
she just didn’t want to get off that ambu-
lance. For the next four years, Bailey worked 
as a paramedic. Her eagerness to know more 
about her patients led her to Jefferson, where 
she is now a third-year student. 
Bailey, 30, says these experiences help her 
maintain perspective on the stresses and 
challenges of medical school. She also draws 
on insights from her years as a high school 
and collegiate pole-vaulter. One might 
assume this sport cultivates courage. But 
Bailey, who routinely launched herself higher 
than 12 feet up and over a bar, is convinced 
that the sport also reinforces traits such 
as persistence, ambition and logic. Always 
trying to anticipate the next step ahead, she 
says, is a trait helpful in medicine.
The Dean’s Column
Interesting people tend to attract others, 
and at JMC, this has been snowballing. While 
medical students with nontraditional educa-
tional and professional backgrounds are but a 
minority on campus, they serve as a magnet 
for other fascinating students. This was defi-
nitely the case for Bianca Grecu, a fourth-year 
student and semi-professional bicycle racer 
with Philadelphia’s Human Zoom women’s 
cycling team. Her path to Jefferson, from 
being an undergraduate public health major, 
included a conventional year off as a clinical 
researcher in anesthesia. Bianca spent much 
of that year racing with her team in national 
races and had the opportunity to guest ride 
in the Nature Valley Grand Prix, a presti-
gious professional race on the USA Cycling 
National Racing Calendar.
Bianca says she chose Jefferson because so 
many students here have interesting back-
grounds that motivate and inspire her. They’re 
good company, she says, and open her eyes to 
new ways of solving problems. Bianca enriches, 
and is enriched by, those around her. 
Medical education today is as much about 
what students learn from one another as what 
they learn from professors. When students 
work together on small-group projects and in 
community outreach settings such as student-
run JeffHOPE clinics, they draw upon one 
another’s collective expertise, scholastic and 
experiential. The unsolicited, uniformly posi-
tive feedback we get from residency program 
directors about our trainees, assures us that 
our emphasis on admitting “whole people” and 
training “the whole physician” is indeed working. 
When Jefferson admits students with 
broad curricular backgrounds and experien-
tial paths, we bring a more worldly and 
informed view to the practice of medicine. 
That’s an important element of our unwritten 
curriculum, as we cultivate the talented 
physicians-in-training who will lead health 
care and public health in the years to come.
Mark L. Tykocinski, MD 
Anthony F. and Gertrude M. DePalma Dean 
Jefferson Medical College
The heart and soul of 
Jefferson are so much 
more than the grades and 
scores of its students – 
they are reflected in their 
life experiences. 
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The hormone receptor guanylyl cyclase C 
(GCC) is a known suppressor of colorectal 
cancer tumors, but new evidence discov-
ered by Jefferson faculty suggests it may 
also help fight one of the country’s biggest 
pandemics: obesity. 
Reporting in the Aug. 25, 2011, online 
issue of the Journal of Clinical Investigation, 
Scott Waldman, MD, PhD, chair of 
the Department of Pharmacology and 
Experimental Therapeutics, and his 
colleagues found that silencing GCC 
affected appetite in mice – disrupting 
satiation and causing obesity. Conversely, 
mice who expressed the hormone receptor 
knew when to call it quits at mealtime. 
Revealing a never-before-shown endocrine 
axis between the intestine and hypothalamus, 
the research could provide novel thera-
peutic targets to control appetite, obesity and 
metabolic syndrome – a combination of 
medical disorders that, when occurring 
together, increase the risk of developing cardio-
vascular disease and diabetes. This presents a 
promising notion given that one-third of the 
U.S. population is considered obese.
Until now, the role of GCC outside the 
gut has remained elusive. Waldman and 
his team have previously shown its role 
as a tumor suppressor and biomarker that 
reveals occult metastases in lymph nodes, 
but GCC’s role in appetite is new and 
surprising territory.
“We were working with GCC-deficient 
mice to look at its role in tumorigenesis in 
the intestine,” Waldman said. “Then the 
mice grew up, and we noticed something: 
They got fatter. We couldn’t understand 
why it was happening, because GCC is 
expressed predominantly in the intestine. 
There was no indication that it regulated 
any function that had to do with metabo-
lism and nutrient uptake.”
To investigate this, Waldman, who also 
leads the Gastrointestinal Malignancies 
Program at the Kimmel Cancer Center 
at Jefferson, and his colleagues raised both 
normal mice and GCC-deficient mice, tracking 
their weight, satiation responses, hepatic and 
serum triglyceride measurements, hormone 
receptor expression and physical activity. 
When the mice digested food, the 
researchers found that the gut released 
hormones into the bloodstream – not just 
within the intestines – and up into the 
brain, where the hormone receptors were 
triggered. Mice with GCC knew when to 
stop, but hormone receptor-deficient mice 
never got the message that their stomachs 
were full. They simply kept eating and 
became obese. 
“They got to be diabetic and developed 
metabolic syndrome, fatty livers and so on,” 
Waldman said. “We ruled out the usual 
suspects. Gastroenterology function was 
normal. They weren’t more sedentary than 
wild type mice; and they did not have 
abnormal metabolism. We realized they just 
had a different appetite.”
The research offers up a new neural-gut 
axis that explains appetite more. But it still 
raises some questions. Do obese people 
possess little to no GCC? And if so, does that 
mean obese people have a genetic disposi-
tion to gain weight? “It’s possible, but it’s 
still unclear,” said Waldman. “There is the 
possibility that obese people do not have 
the receptor or they do not release enough 
hormones to trigger the receptor. More 
studies are needed to better explain this.”
“Obesity could be biological, and not 
behavioral,” said Waldman. “There is no 
evidence here that confirms that. However, 
this new information opens that possibility.” 
Could a Tumor Suppressor Also Fight Obesity?
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That was a high point, but only 
one of many. Daily phone calls 
from each of her six grand-
children punctuated the 14 
months following her diagnosis 
with advanced bile duct cancer. 
Throughout that time, Ariff 
also inspired a vibrant commu-
nity of friends at her synagogue 
with her zest for life and stylish 
hats, which protected her 
during a life-extending thera-
peutic regimen.
“We saw a woman living, not 
dying,” recalls Ariff ’s daughter, 
Sharon Webb, who shared these 
memories in the hope that 
other patients might benefit 
from the experimental photo-
dynamic therapy that let her 
mother experience these joyful 
moments. Ariff passed away in 
October 2010 at age 83, having 
outlived the usual prognosis of 
three to six months.
One month before her death, 
Gladys Ariff danced until 2 a.m. 
at her grandson’s wedding.
Ariff refused chemotherapy 
and radiation; with so little 
time left, she wasn’t willing 
to endure their debilitating 
side effects and limited 
impact on life expectancy. Her 
Wilmington, Del., physician 
referred her to David Loren, 
MD, associate director of 
medical endoscopy at Jefferson, 
who has treated nearly 30 
bile duct cancer patients with 
photodynamic therapy since 
2009 – extending their lives 
post-diagnosis typically by a 
year or more.
While photodynamic therapy 
has been the standard of care 
in Europe for more than two 
decades, it is not offered widely 
for bile duct cancer in the United 
States. The therapy has not 
yet received FDA approval for 
this use, though it is approved 
for some esophageal and lung 
cancers. Only four medical 
centers in the United States treat 
an estimated total of 100 patients 
annually with photodynamic 
therapy for bile duct cancer: 
the Mayo Clinic, Weill Cornell 
Medical College, Indiana 
University and Jefferson.  
Loren is currently recruiting 
patients to participate in a multi-
center clinical trial expected to 
begin this year. Pinnacle Biologics, 
which makes Photofrin®, the 
photosynthesizing medication 
used in the therapy, is funding 
the trial.
By the time symptoms 
appear, the timeline is virtually 
the same for bile duct cancer 
and the more common pancre-
atic cancer. In the United 
States, 3,000 patients receive 
the diagnosis of bile duct cancer 
annually. Typically they have 
experienced jaundice, weight 
loss and itching as tumors 
block the flow of bile from the 
liver into the small intestine, 
where bile plays a key role in 
digestion. While the disease 
may be considered curable 
by surgery in its early stages, 
most patients don’t find out 
in time. When surgery is still 
possible, the odds of extending 
life expectancy through surgery 
or photodynamic therapy are 
often evenly matched. 
Currently, more than 70 
percent of bile duct cancer 
patients hear the grim news 
that their cancer cannot be 
surgically removed. Their 
limited treatment options 
include radiation and chemo-
therapy that degrade quality 
of life during a patient’s final 
months, and stents to keep the 
bile duct open. Unfortunately, 
says Loren, these stents typi-
cally become useless after 
tumor regrowth clogs the ends. 
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artificial light. These prevent 
sunburn triggered by the photo-
active medication. While the 
treatment can be combined 
with chemo and radiation, most 
patients don’t choose this option.
In keeping with her upbeat 
personality, Ariff embraced the 
restrictions on light exposure 
with gusto, triggering a fashion 
phenomenon. Rejecting the hat 
supplied by the hospital, she 
asked her milliner to expand her 
wardrobe of stylish hats. In soli-
darity, her friends likewise wore 
their silliest and most colorful 
hats in her presence. They were 
a vivid sight at her Wilmington 
synagogue, where Ariff also 
inspired a community of volun-
teers to cater life-cycle events. 
Her daughter recalls how every 
woman among the 300 people at 
Photodynamic therapy 
offers the prospect of an extra 
year of life to patients who 
must suddenly confront their 
mortality. “What people are 
looking for is to have extra 
time with the people they love 
and to not be burdened by the 
side effects of chemotherapy 
and radiation,” says Loren.
Photodynamic therapy keeps 
bile duct tubes open by coring 
them like an apple. Patients are 
injected with photosensitizing 
medication two days prior to the 
two-hour endoscopic procedure, 
which delivers tumor-killing 
light via a 4-millimeter laser 
fiber threaded carefully down 
through the intestines and into 
the bile ducts. The bile ducts 
are reopened via bursts of laser 
light focused on tumors, and 
then stents are placed to keep 
bile flowing. After treatment, 
patients typically experience a 
pain-free three months with no 
need to visit a doctor, and then 
return for another round.
For up to six weeks after the 
therapy, patients must wear 
hats and protective clothing to 
block exposure to sunlight and 
“We saw a woman living, not dying.” — Sharon Webb, Ariff’s daughter
Ariff ’s funeral wore a hat: “Her 
style became everyone’s style, 
which added a touch of fun to 
that time of sorrow.”
Restrictions on light exposure 
in the aftermath of this therapy 
are a deterrent for a significant 
subset of patients. “For patients 
who want to be outside, on the 
beach or gardening, photo-
dynamic therapy would not 
improve their quality of life,” 
Loren says. His long-term goal is 
to develop a multifaceted treat-
ment center for bile duct cancer 
at Jefferson to treat more bile 
duct cancer patients with photo-
dynamic therapy and other 
innovative therapeutics. “We 
have other novel options avail-
able for patients. But they are as 
yet unproven while we collect 
data,” he says. Jefferson has one 
of the nation’s highest-volume 
interventional endoscopy units, 
providing 20,000 procedures 
each year, and the expertise of 
dedicated pancreaticobiliary 
surgeons and gastrointestinal 
oncologists.
Michel Kahaleh, MD, chief 
of advanced endoscopy at Weill 
Cornell Physicians and primary 
investigator of the upcoming 
clinical trial for photodynamic 
therapy, says, “The good news 
is that photodynamic therapy 
can downstage cancer if you 
detect it early enough so that 
the lesion can become surgi-
cally resectable. Jefferson has 
become a major partner in the 
fight against bile duct cancer.”
Bile duct cancer has become 
a death sentence unneces-
sarily, says Kahaleh. “Academic 
medical centers must increase 
public awareness and accelerate 
the process to get FDA approval 
for photodynamic therapy. We 
are obligated to take a stand and 
educate patients and doctors to 
promote early detection, treat-
ment and a potential cure.”
However, adds Kahaleh, 
“The real challenge is that this 
is a totally unrecognized and 
under-diagnosed disease. A lot 
of people walk around with 
bile duct cancer unrecognized 
and then die from obstruc-
tive jaundice and infection. If 
doctors would refer them for 
an endoscopic evaluation to 
identify whether their bile duct 
is constricted, we would be 
detecting way more bile duct 
cancer nationally. And if we 
could search for it earlier and 
more aggressively, the prog-
nosis would be much better.”
The price of the photosensi-
tizing medication, Photofrin®, 
recently increased sixfold, 
bringing the total price tag 
to $20,000 for each treatment 
provided at 90-day intervals. 
Medicare typically covers the 
therapy, but other insurers 
sometimes balk. Loren has 
worked tirelessly to reduce 
approval times with other 
insurers even though it some-
times takes him many hours to 
fight on behalf of a patient. He 
notes that the typical three-  
to five-week approval timeline 
just doesn’t make sense for 
someone who has only three 
to six months to live. “I haven’t 
lost yet,” says Loren. “The 
strong clinical data for this 
treatment ultimately persuaded 
independent review boards to 
cover photodynamic therapy 
treatments.”
After Ariff ’s death, Loren’s 
clinic planted trees in her 
memory and mailed a card 
to her family recalling how 
“She brought light and joy to 
everyone.” Inspired by that 
insight, her family inscribed 
the phrase on Ariff ’s tomb-
stone – just below the outline 
of a jaunty hat. 
“ If doctors would refer patients 
for an endoscopic evaluation to 
identify whether their bile duct 
is constricted, we would be 
detecting way more bile duct 
cancer nationally.”
L to R: Jason Giordano, CRNA; 
Jason Lewis, MD; Ayana Williams-
Smith, ORT, ATS; and David Loren, MD, 
in one of Jefferson’s endoscopy suites.
—  Michel Kahaleh, MD, chief of advanced endoscopy, 
Weill Cornell Physicians
Everyone knows that a peanut butter and jelly sandwich can be a culinary death sentence for someone with a 
severe peanut allergy.
Yet few people understand the poten-
tially serious health consequences of eating 
foods with even small quantities of gluten, a 
protein found in wheat, rye and barley, for 
people with celiac disease. 
For people who have celiac disease, a weekly 
communion wafer can lead to life-threat-
ening health problems. This autoimmune 
response to foods with gluten attacks and 
disrupts basic cellular repair mechanisms 
throughout the body and blocks the absorp-
tion of nutrients from food. 
“Celiac disease has a protean and insid-
ious effect throughout the body,” says 
Anthony DiMarino Jr., MD, the William 
Rorer Professor of Medicine and chief 
of the Division of Gastroenterology and 
Hepatology at Jefferson and co-director of 
the Jefferson Celiac Center, which opened 
in early 2011. With 30 physicians, specially 
trained pathologists and a dedicated nurse 
practitioner, the center is one of the largest 
and most integrated providers of care for 
celiac disease patients in the Philadelphia 
region. It’s also the only Center City clinic 
with a full-time registered dietician who 
specializes in helping patients adapt to the 
strictly gluten-free diet required to restore 
their health. 
A Stealth Disease
Unfortunately, celiac is a stealth disease. 
Half of those with the disease are symptom 
free while they accumulate cellular damage. 
Those with symptoms typically seek relief 
for one or more ailments but usually don’t 
realize they need treatment for the root cause. 
They may experience miscarriages, stomach 
pain, weight loss, anemia, migraines, osteo-
porosis, changes in bowel habits, numbing 
and tingling in hands and feet and tiny blis-
ters on elbows, arms and knees. 
“Anyone with these symptoms, an autoim-
mune condition or a family history should 
have a simple diagnostic blood test for celiac,” 
says David Kastenberg, MD, co-director of 
the Celiac Center. “Our job is to educate 
physicians so they know what to look for.” 
The blood test measures anti-tissue trans-
glutaminase or anti-endomysial antibodies, 
indicators of celiac. Even when these anti-
bodies aren’t present, a genetic test can 
reveal the presence of the disease. A human 
leukocyte antigen (HLA) serotype of DQ2 
or DQ8 will show up among 98 percent of 
patients with the disease as well as among 30 
percent of patients without celiac. A biopsy 
of the small intestine, obtained via upper 
endoscopy, confirms the diagnosis.
You Can Never Cheat
Symptoms can be controlled with a strictly 
gluten-free diet – with the emphasis on 
strict. Daily limits on gluten consumption 
are equal to 1/50th of a slice of bread and 
are easily reached via trace contaminants. 
“Basically, you can never cheat,” says Emily 
Rubin, RD, LDN, the division’s dietician. “I 
try to focus on what patients can eat, not on 
what they can’t eat, so that it doesn’t seem 
so overwhelming. Everyone who follows a 
gluten-free diet should feel better within a 
couple of weeks and see their numbers come 
down within six months and normalize 
within a year.” 
The big problem lies with trace contami-
nants. A hamburger can’t just be plucked 
off a bun. Eggs can’t be cooked on the same 
grill as pancakes. Even a peanut butter jar 
can’t be shared with someone who spreads 
it on bread; it might contain crumbs. The 
experience of dining at a restaurant, being 
a guest at a party or eating a home-cooked 
meal can be fraught. “This disease is socially 
challenging,” says Rubin. “Because you feel 
like it’s annoying to nitpick.” 
Currently, celiac disease affects 1 percent 
of Americans. A Mayo Clinic study found 
a nearly fivefold increase in celiac disease 
incidence in current blood samples compared 
with peer samples collected at Warren Air 
Force Base in Wyoming during the 1950s. 
Because the data are grounded in actual blood 
measurements, the study demonstrates that 
the increase in celiac disease is not just a reflec-
tion of growing awareness and diagnosis. By 
Celiac Disease:  
Overcoming a Stealth Public Health Menace
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The extra 15 yards Norm added to his golf drive have attracted even more attention off 
the links than on. 
That’s because he was among six Jefferson patients to participate in a recent multi-
center clinical trial for a promising new medication for celiac disease, larazotide acetate. 
For the prior 15 years, Norm had been unable to get his antibody levels under control. 
During the trial, he didn’t know whether he was receiving a placebo or the actual 
medication, but Norm was thrilled with the results: he gained 30 pounds and improved 
his drive. As soon as the trial ended, he had to stop his medication, which is not yet on 
the market. Both benefits disappeared. 
Six months after the study, Anthony DiMarino Jr., MD, co-director of the Jefferson Celiac  
Center, was permitted to break the blind. He learned that four out of six of his patients 
who had participated in the clinical trial had actually received the medication; their 
antibody counts had improved to normal levels. 
“We hope this will be the next big thing,” says DiMarino, who is currently enrolling 
patients in another clinical trial for larazotide acetate. “What’s so attractive is its safety: 
it doesn’t get into the bloodstream or alter the immune system, blood pressure or heart 
rate. You may be able to take it 30 minutes before a meal, and it tightens up the cells in 
the intestine to block the absorption of accidentally consumed gluten.” 
DiMarino, who has no financial connection to the medication or the company that makes 
it, says, “If you lived in a bubble and never ate gluten again, celiac disease would go 
away. With this medication, you can stay healthy and live in the real world. It should 
protect you from the harmful effects of gluten if you’re not sure how food was prepared. 
The truth is that gluten is so ubiquitous that it’s incredibly difficult to remove from  
your diet.”
While this medication has potential to become the first FDA-approved drug for celiac 
disease, it’s not there yet. In the meantime, Jefferson is engaged in a full range of 
proven diagnostic and therapeutic regimens while also advancing understanding of ways 
to diagnose and care for patients with celiac disease.
To reach the Jefferson Celiac Center,  
call 215-9-CELIAC (or 215-923-5422).
A symptom checklist for celiac disease  
is available at www.celiaccentral.org. 
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assessing mortality rates among servicemen 
from the 1950s whose frozen blood samples 
revealed they had undiagnosed celiac disease, 
the same study revealed a fourfold increase in 
premature death.
Possible factors in the rising incidence of 
celiac disease include the increased gluten 
content of grains due to hybridization and 
comparable increases in food allergies that 
some attribute to the hygiene hypothesis (a 
theory that the modern environment is so 
clean that the immune system turns on itself).
Patients with celiac disease who fail to 
maintain a gluten-free diet have an elevated 
risk of developing intestinal lymphoma or 
bowel cancer. Other serious problems occur 
when the immune system, responding to 
proteins in gluten, permanently damages 
the villi, the hair-like projections that line 
the small intestine like a shag carpet and 
help the body absorb nutrients. A condition 
called refractory sprue affects fewer than 1 
percent of celiac patients, who then cannot 
respond to a gluten-free diet because the 
interior of their intestines has been perma-
nently damaged – rather than a shag carpet, 
the intestines look more like a tile floor, with 
no villi present. Poor absorption of nutri-
ents typically leads to a need for long-term 
steroid therapy and frequent hospitaliza-
tions for these patients. 
Disease du Jour?
In some ways, celiac disease has become a 
victim of greater visibility. It is sometimes 
mistakenly associated with gluten sensitivity, 
a far less serious condition akin to lactose 
intolerance. People with gluten sensitivity 
feel better when they eat less gluten – 
but eating wheat, rye or barley doesn’t affect 
their health.
People with celiac disease also encounter 
skepticism because gluten-free eating has 
joined the ranks of trendy diets – along the 
lines of South Beach and Atkins. “I actually 
had a doctor [not from Jefferson] say to me, 
‘Oh, you have the disease du jour. Aren’t you 
in high fashion?’” recalls Alice Bast, who 
was diagnosed with celiac disease in 1994. 
By that time, Bast, at 5’9” tall, weighed just 
over 100 pounds and had suffered a full-term 
stillbirth, three miscarriages and virtually the 
full checklist of celiac symptoms. “I tell physi-
cians that celiac disease is one of the most 
common yet most under-diagnosed autoim-
mune diseases out there. Please take it seriously. 
Only 200,000 people in the United States have 
been properly diagnosed, and almost three 
million actually have the disease.”
Bast became a patient of DiMarino in 1998. 
Five years later, she founded a nonprofit, the 
National Foundation for Celiac Awareness 
(NCFA), and asked DiMarino to join her scien-
tific and medical advisory board, a role he’s 
held ever since. NCFA offers free continuing 
medical education courses to physicians 
online, facilitates research and initiatives to 
improve the quality of life for individuals with 
the disease, and even trains restaurant chefs 
and food-service managers so that children 
can eat safely in school cafeterias. 
All too often, Bast hears from people who 
don’t have sufficient medical support for 
their disease. “It’s not like you get diagnosed 
with celiac disease and go on your merry 
way. There is so much follow-up to be done,” 
she says. “It needs to be carefully managed.” 
More than a decade ago, DiMarino 
counted himself among the skeptics about 
celiac disease. Then, two of his fellows 
enlisted his help in a study in which they 
determined that fewer than 50 percent of 
obstetricians, gastroenterologists and 
primary care physicians understood the 
link between celiac disease and miscar-
riage. “One of the signs of celiac is a woman 
who has lost multiple pregnancies,” says 
DiMarino. “This research has sparked my 
involvement ever since.”
He vividly recalls one patient, a woman 
in her early 30s who looked like the picture 
of good health. Yet she had lost two full-
term pregnancies and suffered a series of 
miscarriages over five years. The woman 
and her husband had spent tens of thou-
sands of dollars trying to get pregnant. 
“Someone finally noticed that she had a 
slightly lowered hemoglobin count and 
referred her to me,” says DiMarino. “She 
was one of those folks who had no, or 
minimal, gastrointestinal symptoms. I put 
her on a gluten-free diet. She was pregnant 
within six months and had another baby 
two years later.” DiMarino keeps pictures 
of the two children in his office today. 
New Celiac Medication  
Could Improve Health – and Golf Swing
Emily Rubin, RD, LDN, 
reviews dietary options.
Anthony DiMarino Jr., MD, and  
David Kastenberg, MD, co-directors  
of the Jefferson Celiac Center.
LIGHT THERAPY  
for a
BLUE PLANET AND BEYOND
Few treatments have emerged in psychiatry 
that have relatively few side effects, are of 
minimal cost and alleviate symptoms in less 
than a week. Fortunately for people who suffer 
from clinical seasonal affective disorder, or 
SAD, light therapy is one of those rare treat-
ments. “It’s striking, in the world of psychiatry, 
how quickly light works as a therapeutic stim-
ulus compared to pharmacological treatments, 
which may take several weeks to provide 
relief,” says George Brainard, PhD, neurology 
professor and director of Jefferson’s Light 
Research Program.
During fall and winter, 14 percent of the 
U.S. population experiences some sub-clin-
ical symptoms of SAD, a type of depression; 
these symptoms sometimes include mild 
weight gain, modest increased need for sleep, 
tendency to be less socially interactive and 
generally feeling worse during the short days 
of late fall and winter. But for an estimated 
2 percent of the population, symptoms can 
be severe and debilitating and may include 
feelings of hopelessness and weakness or 
thoughts of suicide. 
Bear-like Behavior 
As its name implies, SAD is different from 
typical depression in that its symptoms recur 
annually in the fall and winter. People with 
SAD also tend to crave carbohydrates and 
may gain 10 to 30 pounds during the darkest 
months of the year, whereas typical depression 
is sometimes associated with loss of appetite. 
Another striking difference is that SAD is 
associated with hypersomnia, while people 
with more typical depression often suffer from 
insomnia. People with SAD tend to sleep from 
10 to 14 hours a day. “The weight gain and 
sleep is similar to bears who store up food for 
hibernation in the winter,” says Brainard. 
Until recently, bright white fluorescent 
light has been the gold standard for treating 
SAD. A 1981 study showed that symptoms 
significantly diminished in seven to 10 days 
when patients sat by a 2-by-4-foot panel of 
bright fluorescent light for up to four hours 
each day. The current standard of treat-
ment is bright white light therapy for 30 
to 60 minutes first thing in the morning 
upon awakening. In the last decade, however, 
Brainard and colleagues have discovered that 
specific wavelengths of light corresponding 
to different colors appear to be more potent 
than others at alleviating SAD symptoms. 
The difference lies not in how we perceive 
the colors, but on an unconscious level. 
Light travels from the retina into the brain 
through two pathways. The more commonly 
known pathway leads to the occipital lobe, 
affecting our vision. The other pathway stim-
ulates biological and behavioral responses, 
in part by triggering the pineal gland, which 
secretes melatonin, the hormone that affects 
sleep and has a role in controlling circa-
dian rhythms. A study by Brainard and his 
colleagues showed the wavelength that has 
the greatest influence on the pineal gland 
is 464 nanometers, which corresponds to 
blue – not coincidentally the color of the sky. 
Red, by contrast, is least effective. 
On the Right Wavelength
In a Phase I clinical trial, just 45 minutes a 
day in front of a blue light panel was shown 
to significantly reduce symptoms of SAD, 
compared with a placebo red light control. 
Blue light also elicited a 50 to 60 percent 
remission rate, similar to bright white fluo-
rescent light, but at a much lower dosage in 
terms of brightness and time. “By getting 
the wavelength right, you can use a gentler 
light, which is an important finding for SAD 
treatment, since it doesn’t cause headaches 
or eye strain like a stronger white light can,” 
says Brainard.
Light therapy devices are commercially 
available in several forms, including light 
panels, workstations, dawn simulators and 
head visors. Most light therapy products 
use white light, but companies like Philips 
are emerging as leaders in the light therapy 
marketplace and now offer products with 
blue light-emitting diodes (LEDs). 
At Jefferson, light therapy research is moving 
beyond SAD treatment. Brainard is working 
with NASA to create a dynamic lighting 
system for the International Space Station, 
with the goal of reducing chronic sleep depri-
vation among astronauts. 
“Astronauts are some of the healthiest people 
in the world, but even the toughest person 
can collapse from chronic sleep depriva-
tion,” said Brainard. Back on Earth, such 
research could have significant implications 
for the 20 percent of the U.S. population 
that works in jobs that require alertness 
long after the sun goes down. What began 
as a treatment for seasonal depression, light 
therapy is helping even the healthiest among 
us sleep (and wake) better. 
George Brainard, PhD
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Jefferson Faculty
A walk through a village in Indonesia when she was 6 years old set 
the course of Kathleen Squires’ life. There, she and her father saw  
a man with bulging legs suffering from a disease she now knows  
as elephantiasis, a rare lymphatic disorder. 
Her compassionate father, whose job with an oil company required 
the family to move to locations around the world, commented how 
unfortunate it was that people there didn’t have access to good 
medical care. “The family legend is that I declared right then that  
I would become a doctor to help people like that,” recalls Squires.
As director of Jefferson’s Division of Infectious Diseases since 
2005, Squires is known for her expertise in HIV clinical care and 
research, which aligns with her lifelong interest in helping disad-
vantaged people. “What’s clear is that this infection has settled into 
a population with few economic resources,” she says. 
Jefferson’s clinic treats more than 1,000 HIV patients annu-
ally, nearly one-third of whom are uninsured or underinsured 
and receive care thanks to a grant from the City of Philadelphia. 
Patients may select established treatment protocols or participate 
in one of five clinical trials currently open to improve treatment 
regimens and evaluate new treatment options. 
“Many of our patients are among the working poor and can’t afford 
HIV medications that typically cost $1,000 a month,” Squires 
says. “This grant enables our clinic to help patients obtain needed 
services and health insurance. It’s also critical to our research: 
unless we provide treatment to people with HIV who are impover-
ished, we won’t be at the forefront of understanding this disease.” 
Under Squires’ leadership, Jefferson’s Division of Infectious 
Diseases provides expert consults to physicians who encounter 
obscure diseases from the developing world as well as ailments 
more typically found in the Philadelphia region. This list 
ranges from pneumonia and Lyme disease to MRSA infections, 
drug-resistant tuberculosis and endocarditis and osteomyelitis, 
infections linked to artificial heart valves or bones, respectively.
Squires recently shared her thoughts on her field and career.
Q. What inspired your interest in HIV research and treatment?
A.  My career began at the dawn of AIDS, which was first 
reported in 1981, the year I graduated from medical school.  
I worked at the epicenter of the epidemic during my fellow-
ship at Weill Cornell Medical College in New York. It has 
been an incredible journey for me since. AIDS has evolved 
from a uniformly fatal infection that caused young, vibrant 
people to wither away and die months after diagnosis into  
a chronic condition managed with a one-pill-a-day regimen. 
  I am especially interested in how men and women fare differ-
ently with antiretroviral therapy. For instance, I’m trying to 
tease out whether higher discontinuation rates for antiretro-
viral therapy among women reflect problems with toxicity, or 
the reality that most HIV-infected women are single parents 
who can’t participate in clinical trial schedules. 
Q.  How has your interest in international travel dovetailed  
with your work?
A.  During my childhood, I lived in Indonesia, Nigeria, Brazil, 
Puerto Rico and Australia. While I have lived in the United 
States since high school, my career has enabled me to continue 
my world travels. Most HIV conferences are held outside the 
United States.
Q.  What do you hope will be the legacy of your contribution  
to medicine?
A.  When I first saw HIV in New York, it primarily occurred 
among gay men. In the medical and lay communities, there is 
still pervasive under-recognition that this sexually transmitted 
disease affects men and women equally. I frequently hear ‘this 
woman has a false-positive HIV test. Can you help me sort  
this out?’ In fact, she often does have HIV. 
  My proudest achievement would be to further contribute to 
public awareness that HIV affects both men and women;  
to identify how this disease affects women, especially during 
child-bearing years; and to define how treatment protocols  
for men and women should differ. 
Q. What advances do you hope to see in HIV treatment?
A.  HIV is an absolutely preventable disease – yet its incidence rate 
hasn’t changed over the last decade. Every year, 60,000 new 
cases of HIV are diagnosed in the United States. Over the next 
decade, I would like to see new infection rates drop and more 
patients receive needed therapies, which would reduce forward 
transmission.
  Most people with HIV live in resource-poor settings. In many 
parts of the world outside the United States and Europe, this 
diagnosis is still a death sentence. While global health initia-
tives are changing that picture, many people share my concern 
that the economy will slow our progress.
Kathleen Squires, MD:  
Working to Make a World of Difference for Patients with HIV
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Until Kanani Titchen was in her 30s, she was more likely to portray 
a physician than to consider becoming one herself. A former actor, 
Titchen is now a fourth-year JMC student. While her path to Jefferson 
may have been circuitous, her theatrical experience informs her work 
with patients today, having taught her how to put herself in other 
people’s shoes. 
After graduating from Tufts University with a dual degree in music 
and psychology accompanied by a fascination with biology, Titchen, 
originally from Hawaii, moved to San Diego, where she half-heartedly 
looked for science jobs. “Something was nagging at me,” she says. “I 
was 21 years old. It was the only time I felt like I could pursue music 
and theater without repercussions.” 
After a few interviews for entry-level science jobs, she realized she 
was not yet ready to pursue science. She needed to give acting a shot.
Titchen was accepted to the repertory company at the Lamb’s 
Players Theater, with which she performed and toured for the next 
four years. In the acting world, being in a repertory company is a 
coveted gig because of the steady work it provides. Still, her salary was 
not enough to live on – so, like many actors, she sought other work 
and taught acting to students in kindergarten through 12th grade. 
Despite her busy and unpredictable schedule, she also volunteered at 
a nonprofit organization working with at-risk youth, teaching them to 
write, produce and perform plays with positive messages. 
After several other acting and teaching jobs in San Diego, Titchen 
moved to New York City to be a sound technician for a short-run 
production on Broadway. In New York, Titchen watched artists much 
older than she still struggling to succeed. It was then that she realized 
it was time for a change. “I needed to break the rhythm,” she says. “I 
needed to be bold and start something new.”
Tapping into her love of science and her undergraduate experience 
in behavioral research, Titchen got a job at an international non-
governmental organization doing research on sexually transmitted 
diseases. The position gave her lab experience and came with an 
education stipend that she used for a physiology course at Columbia 
University. She fell in love with the subject matter. 
Even though a medical degree was still a distant thought at the 
time, she enrolled in Columbia’s post-baccalaureate program. “I 
figured I’d get the basic credits out of the way and then decide what 
to do,” she explains. A job at an emergency room clinched the idea of 
medical school. “Finally, my skills working with people and science 
were coming together,” she says.   
Titchen, 36, is among a small subset of older students on campus. 
As such, she appreciates Jefferson’s size and the vibrant connections 
formed among peers and mentors who, like her, experienced other 
careers prior to medicine. Titchen plans to become a pediatrician, a 
specialty she hopes will allow her to incorporate advocacy and preven-
tive medicine. “I just love pediatrics,” she says. “It’s the greatest feeling 
to see a kid go from miserable to smiling.”
As a soon-to-be JMC graduate and pediatrician, the stage is set for 
her career’s second act. 
For Former Actor, Pediatrician 
is the Role of a Lifetime 
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Dean’s Pilot Programmatic Research 
Grant Initiative Awards Announced
JMC Dean Mark L. Tykocinski, MD, 
announced recipients of the Dean’s Pilot 
Programmatic Research Grant Initiative for 
2011 in October. These $50,000 awards are 
used to provide seed money for the genera-
tion of data leading to the submission of 
successful NIH programmatic grants. In the 
latest funding cycle, the awardees were:
Liu Named Director of  
Radiosurgery Physics at JHN
Haisong Liu, PhD, associate professor in 
the Department of Radiation Oncology, has 
been named director of radiosurgery physics 
for the Division of Stereotactic Radiosurgery 
at Jefferson Hospital for Neuroscience. For 
the past three years, Liu has worked in the 
Bodine Center for Radiation Therapy at the 
Kimmel Cancer Center as a senior physicist. 
•	 Karen Knudsen, PhD, Department of 
Cancer Biology
 Prostate Cancer Working Group
•		Gyorgy Hajnoczky, MD, PhD, Department 
of Pathology, Anatomy & Cell Biology
 Mitochondrial Pathogenesis Working Group
•	 Sue Menko, PhD, Department of Pathology, 
Anatomy & Cell Biology 
 Vision Research Center
Liu SchlaffKnudsen Hajnoczky Menko
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Oshinsky Honored by Headache Society
Michael L. Oshinsky, PhD, assistant professor 
of neurology and a member of the Jefferson 
Headache Center team, received the 2011 
Harold G. Wolff Lecture Award for creating a 
new animal model of migraine headache. The 
award is granted annually by the American 
Headache Society for the best paper on head-
ache, head or face pain and the nature of pain 
itself. Oshinsky won for his research paper, 
“Spontaneous Trigeminal Allodynia in Rats: A 
Model of Primary Headache.”
Rattan Awarded $1 Million NIH Grant
Satish C. Rattan, DVM, professor of medi-
cine in the Division of Gastroenterology 
and Hepatology, was awarded a grant for 
more than $1 million by the National 
Institutes of Health to continue his research 
on rectoanal motility disorders. Rattan’s 
laboratory has been pursuing studies to 
determine the factors that regulate basal 
tone in the internal anal sphincter muscle. 
This grant is one of the longest continu-
ously funded grants by NIH. 
Schlaff Named Chair of Ob-Gyn
William Schlaff, MD, has been appointed 
chair of the Department of Obstetrics 
and Gynecology. Schlaff comes from the 
University of Colorado School of Medicine, 
where he was chief of reproductive endocri-
nology and infertility and where he founded 
the division of reproductive endocrinology. 
He has been continuously funded by the 
National Institutes of Health for 15 years.
Most
Sergio Jimenez, MD (seated, far right), professor in the Department of Dermatology  
and Cutaneous Biology, co-director of the Jefferson Institute of Molecular Medicine and 
director of the Division of Connective Tissue Diseases, was invested as an Honorary 
Fellow of the Royal College of Physicians in recognition of his exceptional services to 
the practice of medicine at a ceremony in London in July 2011. Royal College President 
Sir Richard Thompson (seated, center) and past president Dame Carol Black (seated, 
second from right) participated in the ceremony. Also pictured are other new fellowship 
recipients and the Royal College Fellows who sponsored their nominations.
Oshinsky Rattan
New Gene Therapy Ready  
for Clinical Trials 
A promising gene therapy developed in 
part at Jefferson’s Center for Translational 
Medicine to prevent and reverse congestive 
heart failure is on the verge of clinical trials.
Reporting in the online July 20, 2011, 
issue of Science Translational Medicine, 
cardiology researchers demonstrated the 
feasibility, long-term therapeutic effective-
ness and safety of S100A1 gene therapy in 
a large-animal model of heart failure under 
conditions approximating a clinical setting.
“The reversal of cardiac dysfunction in 
this preclinical heart failure model in the 
pig – by restoring S100A1 levels in practi-
cally the same setting as in a patient – is 
remarkable and will pave the way for a clin-
ical trial,” said Patrick Most, MD, adjunct 
assistant professor of medicine at Jefferson 
and lead author of the study. 
Leukemia Drug Could Help  
Breast Cancer Patients 
A leukemia chemotherapy drug may help 
breast cancer patients who don’t respond 
to tamoxifen obtain therapeutic benefits, 
according to a study led by Michael P. 
Lisanti, MD, PhD, professor and chair of 
the Department of Stem Cell Biology and 
Regenerative Medicine and a member of 
the Kimmel Cancer Center. The findings 
were reported in the Aug. 1, 2011, issue of 
Cell Cycle. 
Research found that tamoxifen combined 
with dasatinib, a protein-tyrosine kinase 
inhibitor, reverses the chemo-resistance 
caused by cancer-associated fibroblasts 
in the surrounding tissue by normalizing 
glucose intake and reducing mitochondrial 
oxidative stress, the process that fuels the 
cancer cells. This combination resulted in 
nearly 80 percent cancer-cell death, the 
team reported – a two- to threefold increase 
compared with tamoxifen alone. 
“The drugs have no effect when they are 
used alone – it’s in unison that they effec-
tively kill the cancer cells in the presence of 
fibroblasts,” said Lisanti. “This opens up the 
door for possible new treatment strategies. 
This ‘synthetic lethality’ may help patients 
overcome resistance in the clinic.”
Jefferson Ranks among Nation’s Best 
Thomas Jefferson University Hospitals again 
achieved top rankings in U.S.News & World 
Report’s 2011 Best Hospitals survey – with 
top marks in a record-setting 11 specialty 
areas. 
U.S.News & World Report ranked Jefferson 
14th nationally for orthopedics and 12th 
nationally for rehabilitation medicine. 
Jefferson was nationally ranked in nine addi-
tional specialties: cancer; gastroenterology; 
geriatrics; gynecology; pulmonology; urology; 
diabetes and endocrinology; neurology and 
neurosurgery; and ear, nose and throat. 
Jefferson also ranked in the top 25 percent of 
hospitals nationally for nephrology, rheuma-
tology and cardiology/cardiac surgery.
Headlines 
Lisanti
People
Sergio Jimenez, MD, 
Honored by Royal 
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Single Vaccines May Protect 
Against Rabies, Ebola
Researchers from Jefferson and other insti-
tutions, including the National Institute of 
Allergy and Infectious Diseases, have devel-
oped single vaccine candidates to protect 
against both rabies and the Ebola virus.
Successfully tested in mice, the bivalent 
vaccines have several advantages over other 
Ebola vaccine candidates that could accel-
erate its development for use in humans 
and primates. Built on the same platform as 
the already approved and financially viable 
rabies vaccine, the new vaccine protects 
at-risk populations against two viruses, 
not just one, making it an effective and 
ideal public health tool. The findings were 
published Aug. 17, 2011, online in the 
Journal of Virology. 
“Many Ebola vaccine candidates have 
been proved effective, but none are close 
to licensure,” said Matthias Schnell, 
PhD, director of the Jefferson Vaccine 
Center and professor in the Department 
of Microbiology and Immunology. “One 
of the challenges is the market. There’s 
a rather limited incentive in creating 
a vaccine for Ebola. But these vaccines 
could change that.”
Medical Frontiers
Schnell
Jefferson Offers New Colonoscopy 
Prep Option
Jefferson gastroenterologists are offering a 
new colonoscopy preparation option designed 
to motivate more people to get colonoscopies 
and to improve prevention of colon cancer.
David M. Kastenberg, MD, associate 
professor of medicine in the Division 
of Gastroenterology and Hepatology, and 
his team found that colonoscopy preparation 
medication taken in two doses separated by 
three hours the same day as the procedure is 
just as effective as typical preparations begin-
ning with medications given the night before. 
Benefits include less sleep loss, less workday 
interference and fewer complaints of side 
effects. Many people refrain from having 
colonoscopies to avoid the time-consuming 
overnight protocol.
Jefferson Launches Wholly Robotic 
Cardiac Surgeries
In September 2011, cardiothoracic surgeons 
at Jefferson began performing wholly robotic 
cardiac surgeries, beginning with a mitral 
valve repair. “This is the next step in the 
advancement of our robotics program,” said 
Howard Weitz, MD, director of the Jefferson 
Heart Institute, the Bernard L. Segal Professor 
of Clinical Cardiology and chief of the 
Division of Cardiology. Jefferson is the first 
hospital in Philadelphia to perform wholly 
robotic mitral valve repair. The Division of 
Cardiothoracic Surgery previously conducted 
partial robotic surgeries using the robotic 
arm for access and better visualization in and 
around the heart. 
Jefferson hosted its Ninth Annual Jefferson 
Awards Gala Nov. 1, 2011, at the 
Philadelphia Marriott Downtown. Every 
year, this event honors two members of 
the Jefferson community whose leadership 
profoundly affects the field of medicine. 
Honorees for 2011 were Howard Weitz, 
MD, the Bernard L. Segal Professor of 
Clinical Cardiology, chief of the Division of 
Cardiology and director of the Jefferson 
Heart Institute; and Ira Lubert, a local 
business leader and philanthropist who 
named the Sidney and Ethal Lubert Plaza on 
Jefferson’s campus in honor of his parents. 
The gala raised more than $1 million for 
advanced heart care programs at Jefferson. 
Jefferson Hosts Ninth 
Annual Awards Gala
Headlines continued 
Longtime Faculty Member Creates Alumni Giving Incentive Fund
Last spring, Robert L. Brent, MD, PhD, a 
JMC faculty member since 1955 who has 
established four endowed scholarships 
at Jefferson, and his wife introduced the 
Robert and Lillian Brent Alumni Giving 
Incentive Fund, which they created 
to increase alumni giving and inspire 
generosity in future graduates. The Class of 
2011 is the first to be part of this program. 
The Brents have made a donation to 
the annual fund in each graduating 
student’s name for the first five years after 
graduation. At the end of five years, the 
class will have an enviable 100 percent 
giving participation. After five years, it will 
be up to the class to continue its 100 
percent giving record. 
Brent has emphasized the importance of 
giving throughout his lengthy career. In 
1974, JMC’s student newspaper published 
an article, “Eight Degrees of Charity,” that 
he submitted as a faculty member. He 
recently revised the piece:
Maimonides, the twelfth century Hebrew 
scholar, described eight degrees of 
charity … The highest degree is to 
provide a means whereby the recipient 
will become self-sufficient and in turn 
be able to contribute to society. In 
all likelihood, Maimonides could not 
have foreseen the plight of the private 
university in the twenty-first century – 
but there is no doubt that he would 
have considered university support 
the highest level of philanthropy. 
Maimonides also said, ‘No one ever 
becomes impoverished by giving charity.’
“I guarantee you that the gratification 
and joy of sustaining an institution of 
education will become a very rewarding 
part of your life,” Brent has told 
Jefferson scholars. “For the students 
that have read the Hippocratic Oath, 
you know that it states that physicians 
are responsible for the education of  
future physicians.”
Brent, a distinguished professor of 
pediatric radiology and pathology at 
Jefferson and at Nemours/A.I. duPont 
Hospital for Children, has received several 
honors recently, including being named 
2011 Castle-Connolly National Physician 
of the Year in recognition of excellence in 
clinical care and receiving the William Liley 
Medal, awarded to pioneers in the field of 
perinatal medicine.
Professor Welcomes JMC  
Students for Thanksgiving
This year marked the sixth Thanksgiving 
dinner for JMC students hosted by 
Joseph Majdan, MD, assistant professor 
of medicine and director of professional 
development at Jefferson, and his wife, 
Anita. Twenty-seven students who 
were unable to travel during the holiday 
joined the Majdans at their home and 
consumed an impressive 30 pounds  
of turkey.
ClassNotes
24   JEFFERSON MEDICAL COLLEGE ALUMNI BULLETIN
for a lifetime of career activities 
that have advanced psychiatry. 
Field lives in Philadelphia.
 ’67
David H. Miller retired in July 2011 
after 38 years of practicing ophthal-
mology. He was a founding member 
of Tri-County Eye Physicians and 
Surgeons in Bucks County, Pa. 
Miller lives in Newtown, Pa.
James A. Sumerson retired from the 
practice of otolaryngology and head 
and neck surgery in July. He reports 
that he had a wonderful career, both 
in private practice and in his asso-
ciation with Jefferson as a clinical 
associate professor. He plans to stay 
on as webmaster for Advanced ENT 
in South Jersey; travel with his wife, 
Helene; and spend more time with 
his four grandchildren. He lives in 
Cherry Hill, N.J.
’70 
Harvey Lefton is president-elect of 
the Philadelphia County Medical  
Society and is hoping to keep in 
the tradition of Dr. Samuel Gross 
who was president in 1853. He lives 
in Huntingdon Valley, Pa.
 ’72
Robert E. Rinaldi is working for 
a weight-loss clinic in Naples, Fla. 
He reports that he and his wife, 
Cynthia, are enjoying both work 
and play in paradise.
 ’74
Joseph R. Berger is entering his 
17th year as chair of the neurology 
department at the University of 
Kentucky and says his research and 
interest in progressive multifocal 
leukoencephalopathy have kept him 
very busy. His oldest son pursued a 
career in medicine and is finishing a  
plastic surgery residency at Stanford. 
Berger lives in Lexington, Ky.
 ’96
Tiffany Hughes has started a 
private practice in Philadelphia 
in psychiatry and psychoanalytic 
psychotherapy. She is enrolled as 
a candidate in psychoanalytic 
training at the Psychoanalytic 
Center of Philadelphia.
 ’99
Benjamin L. Hoch, associate 
professor of surgical pathology 
at the University of Washington 
Medical Center, has been promoted 
to director of the school’s residency 
training program. Residents in the 
pathology department recently 
presented him with an outstanding 
teacher award. Hoch lives in 
Snohomish, Wash.
 ’00
Michael A. Baumholtz welcomed 
his second child, Audrey, in 
April 2011. He works in Temple 
University School of Medicine’s 
division of plastic and reconstructive 
surgery and lives in Wynnewood, Pa.
 ’07
Meghan Raleigh recently returned 
from Tikrit, Iraq, where she served 
as a U.S. Army battalion surgeon 
for the 4th Infantry Division. She 
reports that she was packing some 
books from a physical therapy 
clinic and found one on shoulder 
injuries in sports written by 
Phillip J. Marone, MD ’57, MS ’07, 
associate dean of JMC alumni 
relations and executive director 
of the JMC Alumni Association. 
“It was like a small piece of home 
to be reminded of Jefferson.  
All of the sports medicine and 
physical diagnosis training I had 
at Jefferson and beyond has  
been high-yield in taking care  
of soldiers,” Raleigh writes. 
  Post Graduate
James Medina, MD, PG, ’02, 
practices emergency medicine in 
Lancaster, Pa., and has released 
an iPhone/iPad application called 
Coaching Wizard to assist soccer 
coaches with real-time game 
management. The app tracks 
individuals’ playing time, assists 
with player substitutions, records 
statistics and assists with email 
communication.
 ’49
Gerald Marks was recently 
honored by the Pennsylvania 
Society of Colon and Rectal 
Surgeons, which has established an 
annual lectureship in his name. He 
is proud to have played tennis with 
his son, Richard Marks, MD ’88, 
in last year’s National Super Senior 
Father and Son Championship, 
in which they received national 
ranking. He lives in Penn Valley, Pa.
L. Roy Newman is retired from 
the solo practice of pediatrics and 
adolescent medicine. He serves as 
a volunteer teacher of first-year 
Jefferson medical students. A resi-
dent of Rydal, Pa., he is a director of 
the Elkins Park, Pa., volunteer fire 
company and provides reading and 
math mentoring to third-graders 
who live in the Northern Liberties 
neighborhood of Philadelphia. 
 ’54
Howard L. Field has received a 
Philadelphia Psychiatric Society 
Lifetime Achievement Award, 
which is given to a Society member 
          y modification of Einstein’s Theory of Relativity holds that the older one gets, the faster time 
moves – especially if you enjoy what you are doing. I’m coming to the end of my term as Alumni 
Association president, and these two years have flown by because I have  
thoroughly enjoyed representing the biggest and best medical school alumni 
in the country.
I would like to thank the people who made this job so much fun, including 
Phil Marone, MD ’57, MS ’07, and his right-hand staffer, Toni Agnes; the 
members of the Alumni Association Executive Committee, especially the 
subcommittee chairs and Marianne Ritchie, MD ’80, who are the bedrock of 
our organization; and past President John Moore, MD, who showed me the 
ropes before sadly passing away last fall. And I give special thanks to Vince 
Armenti, PhD ’79, MD ’82, who will assume the presidency this April. He has 
always been here for me and will represent us well over the next few years.
And, of course, I thank the thousands of alumni who make up this great organization. I leave you with 
one last thought. JMC has given us all lifelong gifts: a stellar education, family, friends and an alma 
mater that is always a source of great pride. Please join your fellow graduates and give back to JMC 
every year. Don’t let any more time pass by before you do so; tomorrow will be here before you know it.
George Valko, MD ’86 
President, JMC Alumni Association
M
THOMAS JEFFERSON UNIVERSITY AND HOSPITALS
Charitable Gift 
A N N U I T Y  P R O G R A M
A charitable gift annuity can provide you with 
payments for life while supporting the mission  
of Jefferson.
The income from a charitable gift annuity is fixed  
at the time of the gift and will not vary over your 
lifetime. With the volatility of the economy  
and interest rates, this type of gift ensures you  
an annual income that will not change.
For more information,  
please contact Jennifer Welsh  
at the Jefferson Foundation  
at 1-877-JEFF-GIFT (toll free)  
or 215-955-9446 (local).
Jefferson Foundation recommends that you consult with your financial adviser on the best way to take advantage  
of this giving opportunity.
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A 16-year-old heir to the inventor of the kitchen blender has just stolen 
and crashed his father’s Ferrari. When he arrives home after the acci-
dent, he collapses on the marble floor of his parents’ mansion. 
Hank Lawson, a concierge physician, happens to be on the scene. He rips 
open the boy’s shirt to find the telltale bruises of hemophilia and quickly 
diagnoses the boy with a pericardial tamponade. Lawson, who has no 
supplies, sends the boy’s girlfriend to gather his Factor VIII blood-clotting 
kit, a razor blade, a Bic pen, duct tape, a plastic bag and a bottle of vodka. 
Using the vodka as a sterilizer, he slices into the boy’s chest with 
the razor and drains blood out of the pericardial sac via the barrel 
of the pen. Then he seals the wound with the bag and duct tape. The 
boy survives. Just another day at the office for Hank Lawson – and 
for Irving Danesh, MD, graduate of Thomas Jefferson University 
Hospital’s first emergency medicine residency class in 1986.  
Danesh, the medical consultant for the USA Network’s show 
“Royal Pains,” devised the fictional scene above, which appeared in the 
show’s first episode. Danesh is involved in all aspects of production, 
including researching bizarre but true medical scenarios; working 
with the show’s writers to develop medical scenes; assuring medical 
accuracy; and advising the prop department on such projects as 
building lifelike chests for Lawson to slice open with razor blades. 
“We had to reshoot that scene after the pump for the gushing blood 
didn’t work,” Danesh explains about the pericardium scene, which 
also led to recognition from the National Hemophilia Foundation for 
promoting public awareness of the disease. “I remember working with 
patients at Jefferson’s hemophilia center. I definitely drew upon my 
experience there for that scene.” 
The show’s creator, Andrew Lenchewski, first approached Danesh at a 
wedding in Los Angeles and told him about his concept for a show about 
a concierge physician to the rich and famous in the Hamptons in New 
York. And when Lenchewski said he wanted the medical scenarios to be 
as real as possible and that he hoped to tap him for his expertise, Danesh 
was excited but skeptical that the show would ever come to fruition. 
A few months later, Danesh, who lives in Boston, received a 
called from Lenchewski. He had sold the show to USA and needed 
Danesh’s help with the medical scenes. Danesh now splits his time 
between consulting on the show in New York and practicing emer-
gency medicine at Lawrence General Hospital in Massachusetts. 
“I am so lucky. The people at my hospital are very kind. They’re 
proud that I work on ‘Royal Pains’ and give me the freedom to work 
part time when the show is in production,” says Danesh, who is also 
writing a novel and is contracted to write a medical book with one of 
the show’s actor’s wives about the so-called “MacGyvers” in the show. 
Named after the 1980s television series that used a similar 
concept, the “MacGyvers” in the world of “Royal Pains” refer to 
scenarios where Lawson improvises to create handy medical tools 
using household items (and often vodka) that save lives. Other than 
the timing (“Sometimes you need to cure a disease in 24 hours on 
the show,” says Danesh), he tries to ensure that the scenarios are 
medically plausible.
Danesh enjoys thinking up “MacGyvers” and finding rare but true 
medical cases for the show, such as when one character acquires lead 
poisoning from buckshot or when a bad lightbulb causes reflex epilepsy. 
Danesh himself admits to a not-so-rare affliction. “I’m a former TV 
addict,” he says. “So seeing how TV is made – about camera angles, 
how to shoot a scene, how to fake drawing blood into a syringe or that 
oatmeal makes great fake vomit – it’s been a blast.” 
Irving Danesh, MD:  
The Physician  
Behind the Scenes
Danesh with “Royal Pains” 
star Mark Feuerstein
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InMemoriam ’38
Paul E. Chodoff, 97, of Bethesda, 
Md., died Aug. 21, 2011. Chodoff 
opened his Washington, D.C., prac-
tice in the late 1940s and continued 
to see patients until he was 92. He 
served in World War II and treated 
returning servicemen and women 
for what would later be called post-
traumatic stress disorder. He is 
survived by four children.
 ’40
William A. Cappiello, 96, of 
Jupiter, Fla., died Jan. 5, 2011. 
Cappiello served in the U.S. Army 
Medical Corps in World War 
II and completed his surgical 
training at Newark City Hospital 
and Presbyterian Hospital in 
Newark, N.J., and at NYU Bellevue 
Hospital in New York. He ran a 
private practice in Levittown, Pa., 
for more than 30 years and served 
as chief of surgery at Rancocas 
Valley Hospital in Willingboro, 
N.J., and St. Mary Hospital in 
Langhorne, Pa. He is survived 
by four sons, William, MD ’76; 
John; Robert; and Richard; and 
six grandchildren. His wife of 45 
years, Elizabeth, died in 1994. 
 ’47
John A. Koltes, 88, of Philadelphia, 
longtime clinical professor of 
psychiatry and human behavior, 
died Sept. 29, 2011. He is survived 
by his wife, Nancy; four children; 
seven grandchildren; and one sister.
Donald E. Stoudt died Aug. 14, 
2010. Stoudt served in the U.S. 
Navy from 1956 to 1958 before 
serving a residency in neurology 
at Georgetown University. He 
then ran a private neurology 
practice in Reading, Pa., until 
his retirement in 1981. He is 
survived by his wife, Mary Lu, 
who completed Jefferson’s diploma 
nursing program in 1954; four 
children; and two grandchildren.
 ’56
James R. Regan, 80, of Bethlehem, 
Pa., died July 20, 2011. Regan was a 
physician internist in private prac-
tice until he retired. He served his 
country honorably during peacetime 
in the U.S. Air Force. He is survived 
by three sons and one daughter.
 ’59
Kenneth P. Johnson, 79, of Lutherville, 
Md., died Sept. 3, 2011. Johnson was 
former chairman of neurology at 
the University of Maryland School 
of Medicine and an internationally 
recognized expert on multiple scle-
rosis. His work led to FDA approval 
of several new treatments for 
multiple sclerosis. Johnson was the 
founder of the Americas Committee 
for Treatment and Research in 
Multiple Sclerosis and was head of 
the Maryland Center for Multiple 
Sclerosis, which he also founded. He 
enjoyed traveling and camping. He 
is survived by his wife, Jacquelyn; 
Raphael Rubin, MD, 55, of Merion, Pa., professor of 
pathology and cell biology and a faculty member at 
Jefferson since 1986, died of brain cancer Sept. 18.
Rubin was an expert on liver pathology. His research 
focused on a kind of cell signaling known as insulin-
like growth factor 1 – an important hormone known 
to keep cancer cells growing. His research has  
been published in more than 100 professional jour-
nals. He was co-editor of the fifth and sixth editions 
of Rubin’s Pathology, a medical textbook first 
published by his father, Emanuel Rubin.
Rubin, who was named physician of the year in 2000 
by the American Liver Foundation, headed Jefferson’s 
liver study unit and worked closely with liver transplant 
teams. Last April, his portrait was unveiled at JMC.
A talented musician who played piano and 
excelled at the violin, Rubin performed as a 
soloist with the Main Line Symphony and with 
the Merion Trio. He played in benefit concerts 
for Jefferson and for Kohelet Yeshiva High 
School in Merion, which his daughters attended. 
He and his wife, Rene Rothstein-Rubin, estab-
lished a science education fund for the school.
In addition to his wife, Rubin is survived by sons 
Jascha, Saul and Judah; daughters Zipporah, Sophie, 
Zahava and Batsheva; two brothers; and a sister.
Raphael Rubin, MD,  
Professor of Pathology and Cell Biology
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three sons; a daughter; a sister; and 
two grandchildren.
 ’68
Theodore J. Skowronski, 68, of 
Dresher, Pa., died Sept. 6, 2011. 
Skowronski worked at Abington 
Memorial Hospital for 41 years. He 
served in the U.S. Army during 
the Vietnam War at Virginia’s 
Kenner Army Health Clinic at Fort 
Lee. His love for aviation spawned 
the opportunity to become a flight 
surgeon, and he made many heli-
copter trips to Walter Reed Army 
Hospital. He played the accordion 
and had a passion for photography. 
He is survived by his wife, Daria; 
two sons, Paul and Greg; and five 
grandchildren.
  Post Graduate
Ping Nan Cheng, MD, PG, ’79, 70, 
died Aug. 24, 2011. Descended from 
Cheng Ch’eng-kung, the merchant 
pirate who established ethnic Chinese 
rule over the island of Taiwan in the 
17th century, he trained in England 
prior to coming to the United States 
to further his neurosurgical acumen. 
He served a neurological surgery resi-
dency at Jefferson. He enjoyed fishing, 
philosophy, attempting (not always 
successfully) to fix things around 
the house and discussing interesting 
neurosurgical cases. He is survived by 
his wife, an obstetrician-gynecologist, 
and two children: a neurologist and 
an emergency medicine physician.
 ’48
Joseph P. Kenna, 88, of York, Pa., 
died Sept. 24, 2010. Kenna served as 
a U.S. Air Force officer during the 
Korean War. During his 50-year career, 
he practiced family and emergency 
medicine as well as surgery. He most 
recently worked at St. Joseph’s Hospital 
in Lancaster, Pa. He is survived by 
his wife of 62 years, Marie; one son, 
Joseph; three daughters, Diane, Karen 
and Denise, MD ’82; six grandchil-
dren; and three great-grandchildren. 
 ’53
Marvin C. Snyder, 82, of Lehighton, 
Pa., died July 22, 2011. Snyder was 
a family physician for 40 years 
and served on the medical staff 
of the Gnaden Huetten Memorial 
Hospital in Lehighton for 35 years. 
He is survived by his wife of 56 
years, MaryAnn; five sons; and  
two daughters.
 ’55
Joseph S. Harun, 86, of Lower 
Gwynedd, Pa., died May 17, 2011. 
Harun opened a dermatology prac-
tice in Philadelphia in 1957. He later 
helped develop penicillamine to treat 
severe arthritis and was involved 
with the development of new uses 
for clofazimine, a drug intended for 
the treatment of tuberculosis that 
researchers discovered also could be 
used to treat leprosy and infections 
in AIDS patients. He is survived by 
his wife of 59 years, Germaine; two 
daughters; and three sons.
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Influenza
Winter is upon us – and so is flu season. Flu season’s 
severity varies depending on factors including the 
strain and virulence of flu virus, how well the season’s 
flu vaccine matches the virus and the percentage of 
the population that has been vaccinated. While the 
flu may be unpredictable from season to season or 
person to person, here are some things we do know 
about the virus.  
Percentage of people between ages 50 and 64 who have 
one or more health conditions that put them at higher risk 
for flu-related complications: 30%  
On average, percentage of U.S. population that gets the flu 
each year: 5% and 20%  
• Peak month for influenza: February 
• Ideal month to get the flu vaccine: September
• Recommended age for receiving flu vaccine: 
    over 6 months 
• Ages at which people are at greatest risk for flu-related 
     complications: < 5 and ≥ 65 
In
 T
ho
us
an
ds
  
Average number of people 
hospitalized annually in the 
United States for flu-related 
complications: > 200,000  
Average number of children younger 
than 5 who are hospitalized due to 
flu-related complications every year 
in the United States: 20,000  
Range of yearly flu-associated deaths 
between 1976 and 2006 in the 
United States: 3,000 to 49,000  
• Body Mass Index that 
     puts people at highest risk 
     for developing flu-related 
     complications: ≥ 40  
Numbers
Figures from the Centers for Disease Control and Prevention.
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